Want to join the conversation?
Drugmaker $VRTX reported a narrower 1Q16 loss driven by product revenue from cystic fibrosis treating drugs Orkambi and Kalydeco. Net loss narrowed to $41.63MM or $0.17 per share from $198.61MM or $0.83 per share last year. Revenue grew to $398.08MM from $138.51MM. Non-GAAP EPS was $0.09 compared to loss of $0.62 per share a year ago.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?